UPDATE: Novo Nordisk Reports Results from First Phase 3 Trial with N8-GP

Novo Nordisk

today announced the completion of pathfinder(TM)2, the first phase 3 trial with long-acting recombinant factor VIII, N8-GP (turoctocog alfa pegol) for haemophilia A patients. Pathfinder(TM)2 is a multi-national trial evaluating safety and efficacy of N8-GP, when administered for prophylaxis and on-demand treatment  in patients with haemophilia A, who are 12 years or older.